| Richard Turner, | |
|
1301 Pennsylvania Ave, Fort Worth, TX 76104-2122 | |
| (817) 250-2890 | |
| Not Available |
| Full Name | Richard Turner |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 1301 Pennsylvania Ave, Fort Worth, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033171764 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | F7246 (Texas) | Primary |
| Entity Name | Pediatrix Medical Group Of Texas Billing Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649377359 PECOS PAC ID: 0042283921 Enrollment ID: O20110907001264 |
News Archive
Discovery Laboratories, Inc. a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today announces that it has entered into an agreement for a new investment of $0.5 million from PharmaBio Development Inc. (PharmaBio), the former strategic investing subsidiary of Quintiles Transnational Corp.
Less than one third of healthcare workers have themselves vaccinated against classic influenza. This reluctance is astounding, firstly because vaccination against influenza viruses is considered safe and effective and secondly because it has been proved to prevent nosocomial transmission of disease to patients—provided at least 50% of employees have been vaccinated.
GE Healthcare, a unit of General Electric Company, today announced that the US Food and Drug Administration has approved Cysview (hexaminolevulinate HCl) for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.
Cancer researchers at Indiana University and their colleagues have discovered how cancer-induced bone destruction causes skeletal muscle weakness.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Turner, 1301 Pennsylvania Ave, Fort Worth, TX 76104-2122 Ph: () - | Richard Turner, 1301 Pennsylvania Ave, Fort Worth, TX 76104-2122 Ph: (817) 250-2890 |
News Archive
Discovery Laboratories, Inc. a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today announces that it has entered into an agreement for a new investment of $0.5 million from PharmaBio Development Inc. (PharmaBio), the former strategic investing subsidiary of Quintiles Transnational Corp.
Less than one third of healthcare workers have themselves vaccinated against classic influenza. This reluctance is astounding, firstly because vaccination against influenza viruses is considered safe and effective and secondly because it has been proved to prevent nosocomial transmission of disease to patients—provided at least 50% of employees have been vaccinated.
GE Healthcare, a unit of General Electric Company, today announced that the US Food and Drug Administration has approved Cysview (hexaminolevulinate HCl) for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.
Cancer researchers at Indiana University and their colleagues have discovered how cancer-induced bone destruction causes skeletal muscle weakness.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
› Verified 1 days ago
Dr. Heidi Danielle Tomlinson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1301 Pennsylvania Ave, Department Of Neonatology, Fort Worth, TX 76104 Phone: 817-250-2892 | |
Rachel Marie Souers, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 801 7th Ave, Fort Worth, TX 76104 Phone: 682-885-6726 Fax: 682-885-6729 | |
Gregory Barker, Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 1500 Cooper St, Fort Worth, TX 76104 Phone: 682-885-2140 Fax: 817-332-2506 | |
Anne Marcum Kirk, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 801 7th Ave, Fort Worth, TX 76104 Phone: 682-885-1475 Fax: 682-885-7520 | |
Hina Aziz Rehman, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1401 W Pulaski St, Fort Worth, TX 76104 Phone: 682-885-8012 Fax: 682-885-8014 | |
Khalid H Syed, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2332 Beverly Hills Dr, Fort Worth, TX 76114 Phone: 817-378-0855 Fax: 817-378-0861 | |
Dr. Phuong Thi Nguyen, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 801 7th Ave, Fort Worth, TX 76104 Phone: 682-885-1475 Fax: 682-885-7520 |